Keywords: anadys, hcv, drug, gets, fda, fast-track, status
Anadys' HCV drug gets FDA fast-track status
Article | 08 December 2008
The USA's Anadys Pharmaceuticals has been granted fast-track designation for its drug candidate ANA598 for chronic hepatitis C virus infection ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
